Large pharmaceutical companies say allowing Medicare to negotiate lower drug prices will stifle innovation in drug development. Read a new op-ed in Harvard Business Review to find out why that’s not so.
Ian Stockwell
Director, Long-Term Services and Supports Policy and Research Unit, Hilltop Institute
